Modulating the tumor immune microenvironment as an ovarian cancer treatment strategy

Expert Rev Obstet Gynecol. 2012 Sep 1;7(5):413-419. doi: 10.1586/eog.12.41.

Abstract

After more than 30 years of iterations of surgical debulking plus chemotherapy, the need for complementary ovarian cancer treatments has become clear. In the ovarian cancer microenvironment, myeloid immunosuppressive leukocytes, lymphocytes, fibroblasts and endothelial cells, as well as their secreted products, surface molecules and paracrine survival factors, all provide opportunities for novel interventions. The potential of targeting microenvironmental elements in ovarian cancer patients is underscored by recently successful anti-angiogenic therapies. The compartmentalized nature of ovarian cancer, its immunogenicity and its accessibility make it an ideal disease for targeting non-tumor host cells. This review discusses the 'state-of-the-art' of the field, with an emphasis on the potential of modulating the activity of abundant microenvironmental immune cells, which govern both angiogenesis and immunosuppression.

Keywords: Ovarian cancer; angiogenesis; dendritic cell; fibroblast; immunotherapy; tumor immunology; tumor microenvironment.